Abliva AB (publ) (NEVPF) Research

Abliva AB (publ) is a pharmaceutical firm focused on developing novel treatments for primary mitochondrial disorders. Its product pipeline features KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions. Another compound, NV354, is undergoing preparations for clinical studies, specifically targeting primary mitochondrial diseases linked to Complex I deficiency. Beyond mitochondrial diseases, the company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for traumatic brain injury. Abliva collaborates with a range of institutions and companies, including Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. Founded in 2000 and based in Lund, Sweden, the company adopted its current name, Abliva AB (publ), in May 2020, having previously operated as NeuroVive Pharmaceutical AB (publ).

Market snapshot

Symbol
NEVPF
Price
$0.03
Day change
0.00%
Market cap
$715.7M
P/E ratio
-4.91x
52-week range
0.01-0.0374
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Alpha Cognition Inc. (ACOGF)
  • Small Pharma Inc. (DMTTF)
  • Herantis Pharma Oyj (HRPMF)
  • IntelGenx Technologies Corp. (IGXT)
  • ImmuPharma plc (IMMPF)
  • MedPeer,Inc. (MDPEF)
  • Mindset Pharma Inc. (MSSTF)
  • Medivir AB (publ) (MVRBF)

Open Abliva AB (publ) (NEVPF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.